Home > Search Results: Epithelial-to-mesenchymal transition
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 5 records in 0.03 seconds.
Articles, 5 records found
Articles 5 records found  
1.
19 p, 995.7 KB Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression / Jolly, Mohit Kumar (Indian Institute of Science) ; Celià-Terrassa, Toni (Institut Hospital del Mar d'Investigacions Mèdiques)
Genetic and phenotypic heterogeneity contribute to the generation of diverse tumor cell populations, thus enhancing cancer aggressiveness and therapy resistance. Compared to genetic heterogeneity, a consequence of mutational events, phenotypic heterogeneity arises from dynamic, reversible cell state transitions in response to varying intracellular/extracellular signals. [...]
2019 - 10.3390/jcm8101542
Journal of clinical medicine, Vol. 8 (september 2019)  
Detailed record - Creative Commons
2.
18 p, 3.3 MB Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells / Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Rafael, Diana (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ; Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Pérez Martín, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Alamo Pindado, Luis (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Casas, Glòria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fernández Caparrós, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Díaz Riascos, Zamira Vanessa. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Abasolo, Ibane. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Schwartz, Simó (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. [...]
2019 - 10.3390/cancers11081058
Cancers, Vol. 11 Núm. 8 (august 2019) , p. 1058  
Detailed record - Creative Commons
3.
16 p, 4.3 MB Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival / Vilardell, Jordi (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Alcaraz Muñoz, Estefania (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Sarró, Eduard (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Trilla, Enric (Hospital Universitari Vall d'Hebron) ; Cuadros, Thais (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ; Plana i Coll, Maria (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ; Pinna, Lorenzo A. (University of Padova) ; Ruzzene, Maria (University of Padova) ; Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Meseguer Navarro, Anna (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Itarte, Emilio (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of renal cancer. STAT3 pathway is altered in these tumors and p-STAT3 Ser727 is an independent prognostic factor for ccRCC. [...]
2018 - 10.18632/oncotarget.23422
Oncotarget, Vol. 9, Num. 5 (January 2018) , p. 5736-5751  
Detailed record - Creative Commons
4.
9 p, 3.4 MB Snail1 expression is required for sarcomagenesis / Alba-Castellón, Lorena (Institut Hospital del Mar d'Investigacions Mèdiques) ; Batlle, Raquel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Francí, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ; Fernández-Aceñero, María J. (Hospital Universitario Fundación Jiménez Díaz) ; Mazzolini, Rocco (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peña, Raúl (Institut Hospital del Mar d'Investigacions Mèdiques) ; Loubat, Jordina (Institut Hospital del Mar d'Investigacions Mèdiques) ; Alameda, Francesc (Hospital del Mar (Barcelona, Catalunya)) ; Rodríguez, Rufo (Hospital Virgen de la Salud (Toledo)) ; Curto Navarro, Josué (Universitat Autònoma de Barcelona. Centre d'Estudis en Biofísica) ; Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ; Munoz, Alberto (Instituto de Investigaciones Biomédicas "Alberto Sols") ; Bonilla, Félix (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Ignacio Casal, J. (Consejo Superior de Investigaciones Científicas. Centro de Investigaciones Biológicas) ; Rojo, Federico (Institut Hospital del Mar d'Investigacions Mèdiques) ; Garcia de Herreros, Antonio (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)
Snail1 transcriptional repressor is a major inducer of epithelial-to mesenchymal transition but is very limitedly expressed in adult animals. We have previously demonstrated that Snail1 is required for the maintenance of mesenchymal stem cells (MSCs), preventing their premature differentiation. [...]
2014 - 10.1016/j.neo.2014.05.002
Neoplasia (New York, N.Y.), Vol. 16, Issue 5 (May 2014) , p. 413-421  
Detailed record - Creative Commons
5.
12 p, 2.2 MB MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Di Tommaso, Luca (IRCCS Humanitas Clinical and Research Institute (Itàlia)) ; Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Losurdo, Agnese (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ; Pérez-Garcia, José (Vall d'Hebron Institut d'Oncologia) ; Masci, Giovanna (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ; Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ; Cortés, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ; Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with